Reducing the toxicity of cancer therapy: Recognizing needs, taking action

Nature Reviews Clinical Oncology

Volumn 9, Issue 8, 2012, Pages 471-478

  Cleeland, Charles S ^a   Allen, Jeff D ^b   Roberts, Samantha A ^b   Brell, Joanna M ^c   Giralt, Sergio A ^d   Khakoo, Aarif Y ^e   Kirch, Rebecca A ^f   Kwitkowski, Virginia E ^g   Liao, Zhongxing ^a   Skillings, Jamey ^h  

^a UNIVERSITY OF TEXAS   (United States)

^b Friends of Cancer Research   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e AMGEN INC   (United States)

^f American Cancer Society Inc   (United States)

^g CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^h PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTHRACYCLINE; ANTIANDROGEN; ANTILEUKEMIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; AROMATASE INHIBITOR; CYTOTOXIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PLATINUM COMPLEX; PROTEIN TYROSINE KINASE INHIBITOR; TAXANE DERIVATIVE;

ADVERSE DRUG REACTION; ANGIONEUROTIC EDEMA; CANCER CHEMOTHERAPY; CANCER GENETICS; CANCER HORMONE THERAPY; CANCER PAIN; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CARDIOTOXICITY; COGNITIVE DEFECT; DEPRESSION; DISTRESS SYNDROME; FATIGUE; FOOD AND DRUG ADMINISTRATION; GASTROENTERITIS; GASTROINTESTINAL TOXICITY; HEALTH CARE POLICY; HEALTH CARE QUALITY; HEART VENTRICLE FAILURE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; IMMUNE DEFICIENCY; ISCHEMIA; LEUKEMIA; MALIGNANT NEOPLASTIC DISEASE; MEDICAL EDUCATION; MEDICAL RESEARCH; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; OSTEOPOROSIS; PATIENT ADVOCACY; PATIENT CARE; PATIENT SAFETY; PERIPHERAL NEUROPATHY; PNEUMONIA; POSTMARKETING SURVEILLANCE; POSTOPERATIVE COMPLICATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; RADIATION INJURY; REVIEW; SKIN TOXICITY; SYMPTOM; THROMBOSIS;

ANTINEOPLASTIC AGENTS; HUMANS; NEOPLASMS; PATIENT CARE PLANNING; POSTOPERATIVE COMPLICATIONS; RADIATION INJURIES;

EID: 84864464562     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2012.99     Document Type: Review

References (84)

1. Centers for Disease Control and Prevention (CDC). Cancer survivors-United States, 2007. MMWR Morb. Mortal. Wkly Rep. 60, 269-272 (2011).
2. Dantzer, R., Meagher, M. W. & Cleeland, C. S. Translational approaches to treatment-induced symptoms in cancer patients. Nat. Rev. Clin. Oncol. http://dx.doi.org/10.1038/nrclinonc.2012.88
3. Segota, E. & Bukowski, R. M. The promise of targeted therapy: Cancer drugs become more specific. Cleve. Clin. J. Med. 71, 551-560 (2004). (Pubitemid 39069533)
4. Fakih, M. & Vincent, M. Adverse events associated with anti-EGFR therapies for the treatment of metastatic colorectal cancer. Curr. Oncol. 17 (Suppl. 1), S18-S30 (2010).
5. Sankhala, K. et al. The emerging safety profile of mTOR inhibitors, a novel class of anticancer agents. Target. Oncol. 4, 135-142 (2009).
6. Shepard, D. R. & Garcia, J. A. Toxicity associated with the long-Term use of targeted therapies in patients with advanced renal cell carcinoma. Expert Rev. Anticancer Ther. 9, 795-805 (2009).
7. Subbiah, I. M., Lenihan, D. J. & Tsimberidou, A. M. Cardiovascular toxicity profiles of vascular-disrupting agents. Oncologist 16, 1120-1130 (2011).
8. Yang, X. et al. Kinase inhibition-related adverse events predicted from in vitro kinome and clinical trial data. J. Biomed. Inform. 43, 376-384 (2010).
9. Bostrom, P. J. & Soloway, M. S. Secondary cancer after radiotherapy for prostate cancer: Should we be more aware of the risk? Eur. Urol. 52, 973-982 (2007). (Pubitemid 47332061)
10. Chaturvedi, A. K. et al. Second cancers among 104,760 survivors of cervical cancer: Evaluation of long-Term risk. J. Natl Cancer Inst. 99, 1634-1643 (2007).
11. Kry, S. F. et al. The calculated risk of fatal secondary malignancies from intensity-modulated radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 62, 1195-1203 (2005). (Pubitemid 40884435)
12. Nieder, A. M., Porter, M. P. & Soloway, M. S. Radiation therapy for prostate cancer increases subsequent risk of bladder and rectal cancer: A population based cohort study. J. Urol. 180, 2005-2009 (2008).
13. Smith, R. E., Bryant, J., DeCillis, A. & Anderson, S. Acute myeloid leukemia and myelodysplastic syndrome after doxorubicin-cyclophosphamide adjuvant therapy for operable breast cancer: The National Surgical Adjuvant Breast and Bowel Project Experience. J. Clin. Oncol. 21, 1195-1204 (2003). (Pubitemid 46894010)
14. Basch, E. et al. Symptom measurement in clinical trials. Conference on Clinical Cancer Research, November 2011 [online], http://www.focr.org/images/ stories/pdf/panel3final110411.pdf (2011).
15. Movsas, B. et al. Decreasing the adverse effects of cancer therapy: National Cancer Institute guidance for the clinical development of radiation injury mitigators. Clin. Cancer Res. 17, 222-228 (2011).
16. Smith, T. J. et al. American Society of Clinical Oncology provisional clinical opinion: The integration of palliative care into standard oncology care. J. Clin. Oncol. 30, 880-887 (2012).
17. Rose, D. E. et al. Prevalence, predictors, and patient outcomes associated with physician co-management: Findings from the Los Angeles Women's Health Study. Health Serv. Res. 47, 1091-1116 (2012).
18. FDA. Drugs: Adverse Event Reporting System (AERS) [online], http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/ AdverseDrugEffects/default.htm (2012).
19. Institute of Medicine (US) Forum on Drug Discovery, Development, and Translation. Emerging safety science: Workshop summary [online], http://www.ncbi.nlm.nih.gov/books/NBK4146/pdf/TOC.pdf (2008).
20. FDA. Safety: FDA's Sentinel Initiative [online], www.fda.gov/Safety/ FDAsSentinelInitiative (2012).
21. American College of Surgeons. Cancer programs: National cancer data base [online], http://www.facs.org/cancer/ncdb/ (2011).
22. National Cancer Institute. Surveillance Epidemiology and End Results [online], http://seer.cancer.gov. 23. Centers for Disease Control and Prevention
23. National Program of Cancer Registries (NPCR) [online], http://www.cdc.gov/cancer/npcr/ (2012).
24. Abernethy, A. P. et al. Rapid-learning system for cancer care. J. Clin. Oncol. 28, 4268-4274 (2010).
25. National Cancer Institute. Factsheet: NCI's clinical trials cooperative group program [online], http://www.cancer.gov/cancertopics/factsheet/NCI/ clinical-Trials-cooperative-group (2012)
26. PatientsLikeMe® [online], http://www.patientslikeme.com (2012).
27. Wicks, P., Vaughan, T. E., Massagli, M. P. & Heywood, J. Accelerated clinical discovery using self-reported patient data collected online and a patient-matching algorithm. Nat. Biotechnol. 29, 411-414 (2011).
28. Oeffinger, K. C. et al. Chronic health conditions in adult survivors of childhood cancer. N. Engl. J. Med. 355, 1572-1582 (2006). (Pubitemid 44547808)
29. ADNI Alzheimer's Disease Neuroimaging Initiative [online], http://adni.loni.ucla.edu (2012).
30. Lacouture, M. E. et al. Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-Associated dermatologic toxicities. Support. Care Cancer 19, 1079-1095 (2011).
31. Busaidy, N. L. et al. Management of metabolic effects (hyperlipidemia and hyperglycemia) associated with anticancer agents targeting the pi3k-Akt-mTOR (PAM) pathway. J. Clin. Oncol. (in press).
32. National Comprehensive Cancer Institute. NCCN Guidelines & Clinical Resources: NCCN guidelines for supportive care [online], http://www.nccn.org/ professionals/physician-gls/f-guidelines.asp#supportive.
33. Ettinger, D. S. et al. Antiemesis clinical practice guidelines in oncology. J. Natl Compr. Canc. Netw. 7, 572-595 (2009).
34. Rodgers, G. M. III et al. Cancer-And chemotherapy-induced anemia. J. Natl Compr. Canc. Netw. 10, 628-653 (2012).
35. Basch, E. et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J. Clin. Oncol. 29, 4189-4198 (2011).
36. Hensley, M. L. et al. American Society of Clinical Oncology 2008 clinical practice guideline update: Use of chemotherapy and radiation therapy protectants. J. Clin. Oncol. 27, 127-145 (2009).
37. Lyman, G. H. et al. American Society of Clinical Oncology guideline: Recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J. Clin. Oncol. 25, 5490-5505 (2007). (Pubitemid 350232226)
38. Eagle, D. & Sprandio, J. A care model for the future: The oncology medical home. Oncology (Williston Park) 25, 571-576 (2011).
39. National Cancer Research Institute. Rapid review of research in survivorship after cancer and end of life care [online], http://www.ncri.org.uk/ includes/Publications/reports/rapid-review-seolc2010.pdf (2010).
40. National Cancer Institute. Division of Cancer Prevention programs & resources: Community Clinical Oncology Program (CCOP) [online], http://dcp.cancer.gov/programs-resources/programs/ccop.
41. National Cancer Institute. Cancer survivorship research: Cancer control and population sciences [online], http://dccps.nci.nih.gov/ocs (2012).
42. Hoofnagle, J. H. Drug-induced liver injury network (DILIN). Hepatology 40, 773 (2004).
43. Stang, P. E. et al. Advancing the science for active surveillance: Rationale and design for the Observational Medical Outcomes Partnership. Ann. Intern. Med. 153, 600-606 (2010).
44. International Conference on Harmonisation (ICH). Safety guidelines [online], http://www.ich.org/products/guidelines/safety/article/safety- guidelines.html (2012).
45. Olson, H. et al. Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul. Toxicol. Pharmacol. 32, 56-67 (2000).
46. Seigers, R. & Fardell, J. E. Neurobiological basis of chemotherapy-induced cognitive impairment: A review of rodent research. Neurosci. Biobehav. Rev. 35, 729-741 (2011).
47. Bowen, J. M., Gibson, R. J. & Keefe, D. M. Animal models of mucositis: Implications for therapy. J. Support. Oncol. 9, 161-168 (2011).
48. Walker, E. A. Animal models. Adv. Exp. Med. Biol. 678, 138-146 (2010).
49. Meagher, M. W. in Cancer Symptom Science: Measurement, Mechanisms, and Management (eds Cleeland, C. S., Fisch, M. J. & Dunn, A. J.) 124-141 (Cambridge University Press, Cambridge UK, 2011).
50. Clement, C. G. et al. Stimulation of lung innate immunity protects against lethal pneumococcal pneumonia in mice. Am. J. Respir. Crit. Care Med. 177, 1322-1330 (2008). (Pubitemid 351860909)
51. Force, T. & Kolaja, K. L. Cardiotoxicity of kinase inhibitors: The prediction and translation of preclinical models to clinical outcomes. Nat. Rev. Drug Discov. 10, 111-126 (2011).
52. Zhang, H., Yoon, S. Y., Zhang, H. & Dougherty, P. M. Evidence that spinal astrocytes but not microglia contribute to the pathogenesis of paclitaxel-induced painful neuropathy. J. Pain 13, 293-303 (2012).
53. Mandenius, C. F. et al. Cardiotoxicity testing using pluripotent stem cell-derived human cardiomyocytes and state-of-The-Art bioanalytics: A review. J. Appl. Toxicol. 31, 191-205 (2011).
54. Turteltaub, K. W. et al. Identification and elucidation of the biology of adverse events: The challenges of safety assessment and translational medicine. Clin. Cancer Res. 17, 6641-6645 (2011).
55. Abernethy, D. R., Woodcock, J. & Lesko, L. J. Pharmacological mechanism-based drug safety assessment and prediction. Clin. Pharmacol. Ther. 89, 793-797 (2011).
56. Reagan-Udall Foundation for the FDA. Projects [online], http://www.reaganudall.org/projects-programs/projects-overview/ (2012).
57. Basch, E. et al. Adverse symptom event reporting by patients vs clinicians: Relationships with clinical outcomes. J. Natl. Cancer Inst. 101, 1624-1632 (2009).
58. Basch, E. M. et al. Electronic toxicity monitoring and patient-reported outcomes. Cancer J. 17, 231-234 (2011).
59. US Department of Health and Human Services, FDA, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research & Center for Devices and Radiological Health. Guidance for industry: Patient-reported outcome measures: Use in medical product development to support labeling claims [online], http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM071975.pdf (2009).
60. Dempke, W. C., Suto, T. & Reck, M. Targeted therapies for non-small cell lung cancer. Lung Cancer 67, 257-274 (2010).
61. Yap, T. A. & Workman, P. Exploiting the cancer genome: Strategies for the discovery and clinical development of targeted molecular therapeutics. Annu. Rev. Pharmacol. Toxicol. 52, 549-573 (2012).
62. Yeung, D. T. & Hughes, T. P. Therapeutic targeting of BCR-ABL: Prognostic markers of response and resistance mechanism in chronic myeloid leukaemia. Crit. Rev. Oncog. 17, 17-30 (2012).
63. Brooks, P. et al. OMERACT 10-International consensus conference on outcome measures in rheumatology clinical trials. J. Rheumatol. 38, 1450-1451 (2011).
64. Wortel, C. H. et al. Interleukin-6 mediates host defense responses induced by abdominal surgery. Surgery 114, 564-570 (1993). (Pubitemid 23264723)
65. Kerawala, C. J. Complications of head and neck cancer surgery -prevention and management. Oral Oncol. 46, 433-435 (2010).
66. Williams, J. P., Johnston, C. J. & Finkelstein, J. N. Treatment for radiation-induced pulmonary late effects: Spoiled for choice or looking in the wrong direction? Curr. Drug Targets 11, 1386-1394 (2010).
67. Abratt, R. P. & Morgan, G. W. Lung toxicity following chest irradiation in patients with lung cancer. Lung Cancer 35, 103-109 (2002). (Pubitemid 34136086)
68. Armstrong, T. & Gilbert, M. R. Central nervous system toxicity from cancer treatment. Curr. Oncol. Rep. 6, 11-19 (2004). (Pubitemid 38898825)
69. Kim, J. H., Brown, S. L., Jenrow, K. A. & Ryu, S. Mechanisms of radiation-induced brain toxicity and implications for future clinical trials. J. Neurooncol. 87, 279-286 (2008).
70. Perry, A. & Schmidt, R. E. Cancer therapy-Associated CNS neuropathology: An update and review of the literature. Acta Neuropathol. 111, 197-212 (2006).
71. Sonis, S. T. Regimen-related gastrointestinal toxicities in cancer patients. Curr. Opin. Support. Palliat. Care 4, 26-30 (2010).
72. Sul, J. K. & DeAngelis, L. M. Neurologic complications of cancer chemotherapy. Semin. Oncol. 33, 324-332 (2006). (Pubitemid 43849929)
73. Cleeland, C. S., Farrar, J. T. & Hausheer, F. H. Assessment of cancer-related neuropathy and neuropathic pain. Oncologist. 15 (Suppl. 2), 13-18 (2010).
74. Hagiwara, H. & Sunada, Y. Mechanism of taxane neurotoxicity. Breast Cancer 11, 82-85 (2004).
75. Mohty, B. et al. Peripheral neuropathy and new treatments for multiple myeloma: Background and practical recommendations. Haematologica 95, 311-319 (2010).
76. Albini, A. et al. Cardiotoxicity of anticancer drugs: The need for cardio-oncology and cardio-oncological prevention. J. Natl Cancer Inst. 102, 14-25 (2010).
77. Curigliano, G., Mayer, E. L., Burstein, H. J., Winer, E. P. & Goldhirsch, A. Cardiac toxicity from systemic cancer therapy: A comprehensive review. Prog. Cardiovasc. Dis. 53, 94-104 (2010).
78. Daher, I. N. & Yeh, E. T. Vascular complications of selected cancer therapies. Nat. Clin. Pract. Cardiovasc. Med. 5, 797-805 (2008).
79. Ahn, S. & Lee, Y. S. Predictive factors for poor prognosis febrile neutropenia. Curr. Opin. Oncol. http://dx.doi./org/10.1097/CCO.0b013e328352ead2 (2012).
80. Greenspan, S. L. et al. Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer. J. Clin. Endocrinol. Metab. 90, 6410-6417 (2005). (Pubitemid 41759293)
81. Krychman, M. L. & Katz, A. Breast cancer and sexuality: Multi-modal treatment options. J. Sex. Med. 9, 5-25 (2012).
82. Di Lorenzo, G. et al. Toxicities of targeted therapy and their management in kidney cancer. Eur. Urol. 59, 526-540 (2011).
83. Force, T. & Kerkelä, R. Cardiotoxicity of the new cancer therapeutics-mechanisms of, and approaches to, the problem. Drug Discov. Today 13, 778-784 (2008).
84. Tesfa, D. & Palmblad, J. Late-onset neutropenia following rituximab therapy: Incidence, clinical features and possible mechanisms. Expert Rev. Hematol. 4, 619-625 (2011).